Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
261-280 of 2,251 trials

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Colorectal Cancer: Flu Vaccine and Pembrolizumab Study

We are exploring whether a flu vaccine combined with pembrolizumab can help shrink tumors in patients with early pMMR colorectal cancer. The study will also assess safety and immune responses.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Ureter Visualization: Nizaracianine Triflutate in Surgery

We are studying a new intravenous drug to help surgeons see the ureters more clearly during abdominopelvic surgeries. This may improve safety and reduce the need for invasive procedures.

Urinary Tract ImagingEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOtolaryngologyUrology

Endometrial Cancer: RAINBO Treatment Study

We are exploring a new treatment approach for patients with endometrial cancer based on their molecular features. The goal is to see if this can improve survival rates and reduce the chance of cancer returning.

Mismatch Repair Deficient High-Risk Endometrial Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Postpartum Anemia: IV vs. Oral Iron Treatment

We are studying whether intravenous iron is more effective than oral iron in reducing postpartum depression and improving anemia in women after cesarean delivery. This trial will help us understand the best treatment options for new mothers facing these challenges.

Postpartum Depression with Iron Deficiency Anemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPsychiatry

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Biliary Tract Cancer: GAP Chemotherapy Study

We are studying whether a combination of chemotherapy before surgery helps patients with biliary tract cancers live longer and have better outcomes than those who undergo surgery right away.

Biliary Tract CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Hearing Loss Prevention: Sodium Thiosulfate for Chemotherapy Patients

We are studying whether transtympanic sodium thiosulfate can help prevent hearing loss in patients receiving cisplatin chemotherapy. This trial will compare its effects on hearing with those of untreated ears.

Head and Neck Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Metastatic Renal Cell Carcinoma: Treatment Comparison Study

We are comparing two treatment combinations for patients with metastatic renal cell carcinoma to see which one improves survival and quality of life. This study is for those who have not received treatment before and have specific risk factors.

Metastatic Renal Cell CarcinomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Ewing Sarcoma: Regorafenib with Chemotherapy

We are studying a new combination of regorafenib and standard chemotherapy for patients with newly diagnosed multimetastatic Ewing sarcoma. The goal is to find the best dose and evaluate its safety and effectiveness.

Metastatic Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Oligometastatic Non-Small Cell Lung Cancer: Immunotherapy with Local Treatments

We are studying whether adding a local treatment to standard immunotherapy helps improve survival for patients with oligometastatic non-small cell lung cancer. This trial will also look at quality of life and side effects.

Synchronous Oligometastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Ovarian Cancer Diagnosis: IMPROCAS Study

We are exploring new blood test methods and imaging techniques to improve how ovarian cancer is diagnosed. This study aims to create a better model for identifying the disease and understanding its severity.

Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal MedicineOncology

Teicoplanin Dosing: Optimized vs. Standard Care

We are studying whether a new dosing method for teicoplanin helps patients achieve better treatment results compared to standard dosing. This trial looks at how quickly patients reach the right drug levels and their overall recovery.

Sepsis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Type 2 Diabetes: BCAA Oxidation Study

We are investigating whether boosting branched-chain amino acid oxidation can lower blood sugar levels in people with type 2 diabetes. The study also examines effects on insulin sensitivity, heart health, and cognitive function.

Type 2 Diabetes6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDiabetologyEndocrinology

E. coli Urinary Tract Infection: Pivmecillinam Treatment

We are studying whether an oral medication called pivmecillinam is as effective as standard treatments for E. coli urinary tract infections. This trial will also assess safety and other health effects.

Febrile Urinary Tract Infection>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesUrology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology